2020
DOI: 10.1158/2159-8290.cd-20-0116
|View full text |Cite
|
Sign up to set email alerts
|

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR–MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion–Driven NSCLC

Abstract: EGFR exon 20 insertion driver mutations (Exon20ins) in non-small cell lung cancer (NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ-61186372), a bispecifi c antibody targeting EGFR-MET, has shown preclinical activity in TKI-sensitive EGFR-mutated NSCLC models and in an ongoing fi rst-inhuman study in patients with advanced NSCLC. However, the activity of amivantamab in Exon20ins-driven tumors has not yet been described. Ba/F3 cells and patient-derived cells/organoids/xenograft … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
155
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 191 publications
(175 citation statements)
references
References 46 publications
(58 reference statements)
1
155
0
Order By: Relevance
“…The preferred BsAb should enable novel biological function and therapeutic MOA which cannot be achieved using mAbs alone or in combination. Basic science supported a key role of c-MET in NSCLC patients developing resistance to EGFR TKIs, supporting design of JNJ-61186372 (EGFR × c-MET BsAb) and patient selection criteria leading to demonstrated anti-tumor activity in NSCLC patients with resistance to EGFR TKIs (Park et al 2020 ; Yun et al 2020 ). Interestingly, duligotuzumab (MEHD7945A), a BsAb targeting EGFR and HER3, showed no clinical benefit in comparison to cetuximab (anti-EGFR mAb) in phase 2 trials in patients with metastatic colorectal cancer or head and neck squamous cell carcinoma.…”
Section: Challenges and Considerations For The Development Of Dual Tamentioning
confidence: 95%
“…The preferred BsAb should enable novel biological function and therapeutic MOA which cannot be achieved using mAbs alone or in combination. Basic science supported a key role of c-MET in NSCLC patients developing resistance to EGFR TKIs, supporting design of JNJ-61186372 (EGFR × c-MET BsAb) and patient selection criteria leading to demonstrated anti-tumor activity in NSCLC patients with resistance to EGFR TKIs (Park et al 2020 ; Yun et al 2020 ). Interestingly, duligotuzumab (MEHD7945A), a BsAb targeting EGFR and HER3, showed no clinical benefit in comparison to cetuximab (anti-EGFR mAb) in phase 2 trials in patients with metastatic colorectal cancer or head and neck squamous cell carcinoma.…”
Section: Challenges and Considerations For The Development Of Dual Tamentioning
confidence: 95%
“…3A). Mobocertinib inhibited viability of CUTO14 cells (IC 50 3C). Potent inhibition of EGFR and downstream signaling by mobocertinib was confirmed in all three cell lines by western-blot analysis ( Fig.…”
Section: Egfr Inhibitory Profile Of Mobocertinibmentioning
confidence: 99%
“…Taken together with the above mass spectrometry results, this is consistent with its mechanism of covalent binding. Mutants inhibited more potently than WT EGFR included all four variants containing common activating mutations with or without the T790M resistance DT, and LT: IC50 : 2.7-21.3 nM), and all five variants containing uncommon activating mutations (G719A, G719S, S768I, L861Q, and L861R; IC 50 s 3.5-20.2 nM). Most importantly, mobocertinib inhibited all five variants containing…”
mentioning
confidence: 99%
“…Amivantamab has been shown to function through multiple mechanisms of action in preclinical models of NSCLC with EGFR exon 20 insertion driver mutations, which cause tumor cells to be insensitive to EGFR tyrosine kinase inhibitors. 98 FDA granted Breakthrough Therapy designation to amivantamab for the treatment of patients with metastatic NSCLC with (EGFR) Exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. A BLA or MAA for amivantamab for NSCLC is included in Janssen’s new molecular entity filings planned during 2020.…”
Section: Antibodies To Watch In 2021: Cancer Indicationsmentioning
confidence: 99%